VirtualScopics Inc. Implements TrialTracker™
ROCHESTER, N.Y., APRIL 21, 2015. VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, announces that they have implemented the imaging data and query management digital platform, TrialTracker™ that was licensed from alliance partner, IXICO plc, in December 2014. Operational metrics from the initial clinical trials that have been deployed using TrialTracker™ have met or exceeded all expectations for performance.
“Imaging sites are at the heart of all clinical trials for VirtualScopics,” said Ron Way, Vice President of Operations at VirtualScopics. “Providing sites with the very best tools for safe, reliable and efficient transfer of this precious research information is why we chose to work with IXICO, and to deploy TrialTracker™ and Site Interface. We expect our deployment to accelerate very quickly, now that our proof points have been met.”
Data Queries are a necessary though burdensome part of almost every clinical trial. Sites using TrialTracker Site Interface can now manage their entire set of image data transfer activities, including transfer dates, compliance with privacy regulations governing personal health information (PHI) and resolution of data queries with a single intuitive application.
“When you make it easier for sites to work with you,” explained Mr. Way, “the outcomes include a faster turnaround time from acquisition to image transfer, a reduced number and faster resolution of data queries as well as substantial reductions in elapsed time before image analysis can begin. That’s a win for the sites, a win for VirtualScopics and most importantly, a big win for our sponsors.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
